Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer

esophageal cancer, gastric cancer, comparative effectiveness research, outcome assessment, antineoplastic agents, immunotherapy

Immunotherapy checkpoint inhibitors are FDA-approved for first-line metastatic esophageal and gastric cancer, but not all scenarios benefit from non-selective chemo-immunotherapy application. ASCO Net Health scores were consistently higher in esophageal cancer trials compared to gastric cancer tr…

Jan 13^th • 8 mins read

Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers

PD-1/PD-L1 inhibitors, ESMO-MCBS, ASCO-VF, value, cost

Only a few treatment regimens showed clinical value in EC and CRC using ASCO-VF and ESMO-MCBS frameworks. Nivolumab met valuable threshold in resectable locally advanced EC/GEJC. 14 positive therapeutic regimens assessed; 11 negative regimens showed no improvement in QoL and were below the …

Apr 21^st • 13 mins read